Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies

(2018) Zhong-Yi Dong et al.   Journal of Thoracic Oncology

Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy

(2018) Pieter-Jan van Dam et al.   SEMINARS IN CANCER BIOLOGY

Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma

(2017) Fumie Igari et al.   HUMAN PATHOLOGY

Melanoma subtypes demonstrate distinct PD-L1 expression profiles

(2017) Genevieve J Kaunitz et al.   LABORATORY INVESTIGATION

A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas

(2016) Laura H. Tang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs

(2016) Seung Tae Kim et al.   Journal of Cancer

Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes

(2016) Sasha E. Stanton et al.   JAMA Oncology

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

Multiplexed immunohistochemistry, imaging, and quantitation: A review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis

(2014) Edward C. Stack et al.   METHODS

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors

(2012) Shinichi Yachida et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

(2012) H. Sorbye et al.   ANNALS OF ONCOLOGY

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

(2012) Andrew V. Biankin et al.   NATURE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors

(2011) Y. Jiao et al.   SCIENCE

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

(2010) Richard E. Royal et al.   JOURNAL OF IMMUNOTHERAPY

KIT is an Independent Prognostic Marker for Pancreatic Endocrine Tumors

(2009) Lizhi Zhang et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Non-functional Neuroendocrine Carcinoma of the Pancreas: Incidence, Tumor Biology, and Outcomes in 2,158 Patients

(2009) Jan Franko et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors

(2008) T. R Halfdanarson et al.   ENDOCRINE-RELATED CANCER